Pharmaceutical News

RSS

Decreasing iron-storing protein expression can enhance action of brain cancer therapy: Researchers

Brain cancer therapy may be more effective if the expression of an iron-storing protein is decreased to enhance the action of therapeutic drugs on brain cancer cells, according to Penn State College of Medicine researchers.

4 Jun 2011

Patent infringement suit filed against Impax Laboratories in connection with Detrol

Impax Laboratories, Inc. today confirms that Pfizer Inc., Pharmacia & Upjohn Company LLC and Pfizer Health AB have filed suit for patent infringement against Impax in the United States District Court for the District of New Jersey in connection with Detrol (tolterodine tartrate) immediate-release, 1 mg and 2 mg tablets.

4 Jun 2011

Research in progress for novel protein kinase inhibitors: GEN

Biotech scientists are working on novel protein kinase inhibitors that are targeting a host of conditions ranging from atherosclerosis to neurodegenerative diseases, reports Genetic Engineering & Biotechnology News.

4 Jun 2011

Medical oncologists confirm benefits of crizotinib in ALK positive lung cancer

A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take it. The drug, called crizotinib, has been in clinical trials since 2006, and the results from the largest group of patients to take it within the first of these clinical trials are being presented at the annual meeting of the American Society of Clinical Oncology.

4 Jun 2011

Bexarotene and erlotinib drugs effective in treating advanced lung cancer

Scientists have identified a drug combination, when used in advanced lung cancer patients, shows a survival advantage in patients who no longer respond to existing therapies.

3 Jun 2011

Preclinical study: Combination therapy of SPX-106 and D-tagatose reduces triglycerides and cholesterol

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its drug candidate, SPX-106, achieved statistically significant reductions in triglycerides and cholesterol when administered in combination with D-tagatose for nine weeks to genetically engineered mice prone to dyslipidemia.

3 Jun 2011

Longer looks: Is American medicine destroying itself?

Ever since Republicans took control of half the country's statehouses this year, the anti-abortion movement has won one victory after another. At least 64 new anti-abortion laws have passed, with more than 30 of them in April alone. The campaign is the largest in history and also the most creative.

3 Jun 2011

Orexigen meets FDA to gain clarity on approval for Contrave NDA to treat obesity

Orexigen Therapeutics, Inc. announced today that it recently met with the Food and Drug Administration (FDA) regarding the New Drug Application for Contrave (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss.

3 Jun 2011

Insight into beneficial epilepsy treatments for children with autism

Physicians will have a better guide for more effectively managing treatment of children experiencing seizures related to autism with the results of a study by researchers at Arizona State University and the University of Texas-Houston.

3 Jun 2011

UC review finds rate of rtPA treatment for ischemic stroke in the U.S. doubled since 2005

In a review of nationwide hospital databases, University of Cincinnati (UC) emergency medicine and neurology researchers have found that the rate of treatment with the standard therapy for acute ischemic stroke patients has doubled since 2005.

3 Jun 2011

Syndax receives U.S. patent for entinostat to treat metastatic cancers

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the United States Patent and Trademark Office of Patent Application Serial No. 12/549458 entitled: " N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL)- METHOXYCARBONYL—AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."

3 Jun 2011

PQA honors Kaiser Permanente for outstanding performance in medication safety

Kaiser Permanente Colorado is one of only three health plans in the nation to receive a top honor for excellence in medication safety. The award, issued by the Pharmacy Quality Alliance, recognizes Kaiser Permanente's outstanding performance on medication safety measures included in the Centers for Medicare and Medicaid Services (CMS) new 5-star rating program.

3 Jun 2011

FDA approves Mylan's ANDA for Venlafaxine HCl ER Capsules to treat depressive, anxiety disorder

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Venlafaxine Hydrochloride Extended-release Capsules, 37.5 mg (base), 75 mg (base) and 150 mg (base), the generic version of Wyeth's Effexor XR Capsules, which are used in the treatment of major depressive disorder and social anxiety disorder.

3 Jun 2011

Repligen announces completion of RG1068 pre-New Drug Application meeting with U.S. FDA

Repligen Corporation today announced that the Company has concluded a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration related to its lead product candidate, RG1068 for improvement of magnetic resonance imaging of the pancreas.

2 Jun 2011

Teva receives FDA approval to market Eisai's Alzheimer's treatment Aricept Tablets in the U.S.

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application to market a generic version of Eisai's Alzheimer's treatment Aricept Tablets, 5 mg and 10 mg. Shipment of this product has commenced.

2 Jun 2011

XTL receives FDA Orphan-drug designation for rHuEPO drug to treat Multiple Myeloma

On May 29, 2011 XTL has announced that its rHuEPO drug which is currently in preparations for phase 2 clinical trial, has been granted an Orphan-drug designation by the US Food and Drug Administration (FDA) for treatment of Multiple Myeloma blood cancer.

2 Jun 2011

China's SFDA grants production license to TPI anti-diabetic drug Gliclazide

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals today announced TPI has received the production license for its anti-diabetic drug Gliclazide Tablets from China's State Food and Drug Administration.

1 Jun 2011

EMA accepts Pfizer's filing of axitinib for regulatory review to treat advanced renal cell carcinoma

Pfizer Inc. announced today that the European Medicines Agency has accepted Pfizer's filing for regulatory review of axitinib for patients with advanced renal cell carcinoma after failure of prior systemic treatment.

1 Jun 2011

Alexion's sBLA for Soliris receives FDA Priority Review designation to treat aHUS

Alexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted the Company's request for Priority Review of its supplemental Biologics License Application for Soliris as a treatment for patients with atypical Hemolytic Uremic Syndrome.

1 Jun 2011

Spanish Medicines Agency grants IMP License to Midatech's clinical grade nanoparticles

Midatech Biogune S. L., the nanoparticle manufacturing subsidiary of the Midatech Group, a global leader and centre of excellence for the design, development, synthesis and manufacture of nanomedicines, is pleased to announce that it has been granted an Investigational Medicinal Products (IMP) License from the Spanish Medicines Agency for the cGMP manufacture of clinical grade nanoparticles at its state-of-the art facility in Bilbao, Spain.

1 Jun 2011

Pharmaceutical News

Decreasing iron-storing protein expression can enhance action of brain cancer therapy: Researchers

Patent infringement suit filed against Impax Laboratories in connection with Detrol

Research in progress for novel protein kinase inhibitors: GEN

Medical oncologists confirm benefits of crizotinib in ALK positive lung cancer

Bexarotene and erlotinib drugs effective in treating advanced lung cancer

Preclinical study: Combination therapy of SPX-106 and D-tagatose reduces triglycerides and cholesterol

Longer looks: Is American medicine destroying itself?

Orexigen meets FDA to gain clarity on approval for Contrave NDA to treat obesity

Insight into beneficial epilepsy treatments for children with autism

UC review finds rate of rtPA treatment for ischemic stroke in the U.S. doubled since 2005

Syndax receives U.S. patent for entinostat to treat metastatic cancers

PQA honors Kaiser Permanente for outstanding performance in medication safety

FDA approves Mylan's ANDA for Venlafaxine HCl ER Capsules to treat depressive, anxiety disorder

Repligen announces completion of RG1068 pre-New Drug Application meeting with U.S. FDA

Teva receives FDA approval to market Eisai's Alzheimer's treatment Aricept Tablets in the U.S.

XTL receives FDA Orphan-drug designation for rHuEPO drug to treat Multiple Myeloma

China's SFDA grants production license to TPI anti-diabetic drug Gliclazide

EMA accepts Pfizer's filing of axitinib for regulatory review to treat advanced renal cell carcinoma

Alexion's sBLA for Soliris receives FDA Priority Review designation to treat aHUS

Spanish Medicines Agency grants IMP License to Midatech's clinical grade nanoparticles

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News